PURPOSE: We investigated the association of bone-only relapse with a pretreatment marker of bone resorption: serum beta C-terminal telopeptide (B-CTx) of type I collagen. METHODS: Pretreatment serum B-CTx concentrations were determined from 621 of 667 patients with primary breast cancer enrolled onto the NCIC CTG MA.14 phase III adjuvant trial of tamoxifen with or without octreotide. Recurrence-free survival (RFS) was a secondary end point; the focus here was bone-only relapse. We analyzed continuous or categorical (.71 ng/mL cut point) serum B-CTx in stepwise forward multivariate Cox regression, adjusted for trial stratification factors. We also examined B-CTx and bone relapse by pretrial chemotherapy status. RESULTS: At median 7.9 years follow-up, 123 of 621 patients experienced recurrence; 19 (3.1%) of 621 had bone-only recurrence, and 47 (7.5%) of 621 had bone plus other sites of recurrence. Larger pathologic tumor size (P = .001) and elevated continuous and categorical serum B-CTx were associated with shorter bone-only RFS (both P = .02) when added to a model with factors significant in the main trial analyses (hazard ratio [HR], 3.43 and 3.50, respectively; 95% CI, 1.20 to 9.77 and 1.26 to 9.75, respectively). The univariate HR for B-CTx was 2.80 (95% CI, 1.05 to 7.48; P = .03). Elevated serum B-CTx was also associated with shorter bone-only RFS (P = .02) when added to a model with factors significant in the main trial analyses. Serum B-CTx level was not associated with any other type of recurrence. Serum B-CTx was not significantly different for patients who underwent pretrial chemotherapy, compared with those who did not (P = .27), nor did pretrial chemotherapy affect bone relapse (P = .48 for bone only; P = .76 for bone with other relapse). CONCLUSION: Higher pretreatment serum B-CTx was a significant predictor of shorter RFS for bone-only metastasis. Increased bone resorption creates an environment that promotes growth of breast cancer cells.
PURPOSE: We investigated the association of bone-only relapse with a pretreatment marker of bone resorption: serum beta C-terminal telopeptide (B-CTx) of type I collagen. METHODS: Pretreatment serum B-CTx concentrations were determined from 621 of 667 patients with primary breast cancer enrolled onto the NCIC CTG MA.14 phase III adjuvant trial of tamoxifen with or without octreotide. Recurrence-free survival (RFS) was a secondary end point; the focus here was bone-only relapse. We analyzed continuous or categorical (.71 ng/mL cut point) serum B-CTx in stepwise forward multivariate Cox regression, adjusted for trial stratification factors. We also examined B-CTx and bone relapse by pretrial chemotherapy status. RESULTS: At median 7.9 years follow-up, 123 of 621 patients experienced recurrence; 19 (3.1%) of 621 had bone-only recurrence, and 47 (7.5%) of 621 had bone plus other sites of recurrence. Larger pathologic tumor size (P = .001) and elevated continuous and categorical serum B-CTx were associated with shorter bone-only RFS (both P = .02) when added to a model with factors significant in the main trial analyses (hazard ratio [HR], 3.43 and 3.50, respectively; 95% CI, 1.20 to 9.77 and 1.26 to 9.75, respectively). The univariate HR for B-CTx was 2.80 (95% CI, 1.05 to 7.48; P = .03). Elevated serum B-CTx was also associated with shorter bone-only RFS (P = .02) when added to a model with factors significant in the main trial analyses. Serum B-CTx level was not associated with any other type of recurrence. Serum B-CTx was not significantly different for patients who underwent pretrial chemotherapy, compared with those who did not (P = .27), nor did pretrial chemotherapy affect bone relapse (P = .48 for bone only; P = .76 for bone with other relapse). CONCLUSION: Higher pretreatment serum B-CTx was a significant predictor of shorter RFS for bone-only metastasis. Increased bone resorption creates an environment that promotes growth of breast cancer cells.
Authors: Christian Bieglmayer; Hans Peter Dimai; Rudolf Wolfgang Gasser; Stefan Kudlacek; Barbara Obermayer-Pietsch; Wolfgang Woloszczuk; Elisabeth Zwettler; Andrea Griesmacher Journal: Wien Med Wochenschr Date: 2012-08-14
Authors: Andrea Decensi; Zhuoxin Sun; Aliana Guerrieri-Gonzaga; Beat Thürlimann; Christina McIntosh; Carlo Tondini; Alain Monnier; Mario Campone; Marc Debled; Astrid Schönenberger; Khalil Zaman; Harriet Johansson; Karen N Price; Richard D Gelber; Aron Goldhirsch; Alan S Coates; Stefan Aebi Journal: Breast Cancer Res Treat Date: 2014-02-01 Impact factor: 4.872
Authors: Vivien H C Bramwell; Alan B Tuck; Judith-Anne W Chapman; Pieter H Anborgh; Carl O Postenka; Waleed Al-Katib; Lois E Shepherd; Lei Han; Carolyn F Wilson; Kathleen I Pritchard; Michael N Pollak; Ann F Chambers Journal: Breast Cancer Res Date: 2014-01-22 Impact factor: 6.466
Authors: Dennis C Sgroi; Judy-Anne W Chapman; T Badovinac-Crnjevic; Elizabeth Zarella; Shemeica Binns; Yi Zhang; Catherine A Schnabel; Mark G Erlander; Kathleen I Pritchard; Lei Han; Lois E Shepherd; Paul E Goss; Michael Pollak Journal: Breast Cancer Res Date: 2016-01-04 Impact factor: 6.466
Authors: C Palmieri; M P Caley; K Purshouse; A-V Fonseca; M Rodriguez-Teja; G Kogianni; L Woodley; J Odendaal; K Elliott; J Waxman; J Sturge Journal: Br J Cancer Date: 2012-12-20 Impact factor: 7.640
Authors: Daniele Santini; Luciano Stumbo; Chiara Spoto; Loretta D'Onofrio; Francesco Pantano; Michele Iuliani; Marco Fioramonti; Alice Zoccoli; Giulia Ribelli; Vladimir Virzì; Bruno Vincenzi; Giuseppe Tonini Journal: Breast Cancer Res Date: 2015-09-02 Impact factor: 6.466
Authors: Alexander Hein; Christian M Bayer; Michael G Schrauder; Lothar Häberle; Katharina Heusinger; Reiner Strick; Matthias Ruebner; Michael P Lux; Stefan P Renner; Rüdiger Schulz-Wendtland; Arif B Ekici; Arndt Hartmann; Matthias W Beckmann; Peter A Fasching Journal: Biomed Res Int Date: 2014-03-05 Impact factor: 3.411